HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/2/H607    most recent 01001.2002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (29) Citing Articles via Google Scholar Google Scholar Articles by Auchampach, J. A. Articles by Gross, G. J. Search for Related Content PubMed PubMed Citation Articles by Auchampach, J. A. Articles by Gross, G. J.

A₃ adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs

Cardiovascular Research Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Submitted 18 November 2002 ; accepted in final form 9 April 2003

We examined the effect of the A₃ adenosine receptor (AR) agonist IB-MECA on infarct size in an open-chest anesthetized dog model of myocardial ischemia-reperfusion injury. Dogs were subjected to 60 min of left anterior descending (LAD) coronary artery occlusion and 3 h of reperfusion. Infarct size and regional myocardial blood flow were assessed by macrohistochemical staining with triphenyltetrazolium chloride and radioactive microspheres, respectively. Four experimental groups were studied: vehicle control (50% DMSO in normal saline), IB-MECA (100 µg/kg iv bolus) given 10 min before the coronary occlusion, IB-MECA (100 µg/kg iv bolus) given 5 min before initiation of reperfusion, and IB-MECA (100 µg/kg iv bolus) given 10 min before coronary occlusion in dogs pretreated 15 min earlier with the ATP-dependent potassium channel antagonist glibenclamide (0.3 mg/kg iv bolus). Administration of IB-MECA had no effect on any hemodynamic parameter measured including heart rate, first derivative of left ventricular pressure, aortic pressure, LAD coronary blood flow, or coronary collateral blood flow. Nevertheless, pretreatment with IB-MECA before coronary occlusion produced a marked reduction in infarct size (40% reduction) compared with the control group (13.0 ± 3.2% vs. 25.2 ± 3.7% of the area at risk, respectively). This effect of IB-MECA was blocked completely in dogs pretreated with glibenclamide. An equivalent reduction in infarct size was observed when IB-MECA was administered immediately before reperfusion (13.1 ± 3.9%). These results are the first to demonstrate efficacy of an A₃AR agonist in a large animal model of myocardial infarction by mechanisms that are unrelated to changes in hemodynamic parameters and coronary blood flow. These data also demonstrate in an in vivo model that IB-MECA is effective as a cardioprotective agent when administered at the time of reperfusion.

heart; infarction

This article has been cited by other articles:

				R. A. G. Patel, D. K. Glover, A. Broisat, H. K. Kabul, M. Ruiz, N. C. Goodman, C. M. Kramer, D. J. Meerdink, J. Linden, and G. A. Beller Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H637 - H642. [Abstract] [Full Text] [PDF]

				T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243. [Abstract] [Full Text] [PDF]

				J. Zheng, R. Wang, E. Zambraski, D. Wu, K. A. Jacobson, and B. T. Liang Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3685 - H3691. [Abstract] [Full Text] [PDF]

				S.-S. Park, H. Zhao, Y. Jang, R. A. Mueller, and Z. Xu N6-(3-Iodobenzyl)-adenosine-5'-N-methylcarboxamide Confers Cardioprotection at Reperfusion by Inhibiting Mitochondrial Permeability Transition Pore Opening via Glycogen Synthase Kinase 3beta J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 124 - 131. [Abstract] [Full Text] [PDF]

				E. R. Gross and G. J. Gross Ligand triggers of classical preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 212 - 221. [Abstract] [Full Text] [PDF]

				T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]

				H. Kin, A. J. Zatta, M. T. Lofye, B. S. Amerson, M. E. Halkos, F. Kerendi, Z.-Q. Zhao, R. A. Guyton, J. P. Headrick, and J. Vinten-Johansen Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine Cardiovasc Res, July 1, 2005; 67(1): 124 - 133. [Abstract] [Full Text] [PDF]

				X. T. Gan, V. Rajapurohitam, J. V. Haist, P. Chidiac, M. A. Cook, and M. Karmazyn Inhibition of Phenylephrine-Induced Cardiomyocyte Hypertrophy by Activation of Multiple Adenosine Receptor Subtypes J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 27 - 34. [Abstract] [Full Text] [PDF]